Trials / Withdrawn
WithdrawnNCT01881958
The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes. The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DiaPep277® |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-01-01
- Completion
- 2017-01-01
- First posted
- 2013-06-20
- Last updated
- 2018-03-06
Source: ClinicalTrials.gov record NCT01881958. Inclusion in this directory is not an endorsement.